BR112020021791A2 - proteínas de fusão de interleucina 12 e composições e métodos terapêuticos das mesmas - Google Patents

proteínas de fusão de interleucina 12 e composições e métodos terapêuticos das mesmas Download PDF

Info

Publication number
BR112020021791A2
BR112020021791A2 BR112020021791-3A BR112020021791A BR112020021791A2 BR 112020021791 A2 BR112020021791 A2 BR 112020021791A2 BR 112020021791 A BR112020021791 A BR 112020021791A BR 112020021791 A2 BR112020021791 A2 BR 112020021791A2
Authority
BR
Brazil
Prior art keywords
fusion protein
seq
subunit
amino acid
acid sequence
Prior art date
Application number
BR112020021791-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Yang-Xin Fu
Hua Peng
Diyuan Xue
Original Assignee
Immune Targeting Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Targeting Inc. filed Critical Immune Targeting Inc.
Publication of BR112020021791A2 publication Critical patent/BR112020021791A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112020021791-3A 2018-04-25 2019-04-24 proteínas de fusão de interleucina 12 e composições e métodos terapêuticos das mesmas BR112020021791A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810376920.1A CN110396133B (zh) 2018-04-25 2018-04-25 一种以白介素12为活性成分的融合蛋白型药物前体
CN201810376920.1 2018-04-25
PCT/US2019/028933 WO2019209965A2 (en) 2018-04-25 2019-04-24 Interleukin 12 fusion proteins, and compositions and therapeutic methods thereof

Publications (1)

Publication Number Publication Date
BR112020021791A2 true BR112020021791A2 (pt) 2021-02-23

Family

ID=68294664

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020021791-3A BR112020021791A2 (pt) 2018-04-25 2019-04-24 proteínas de fusão de interleucina 12 e composições e métodos terapêuticos das mesmas

Country Status (9)

Country Link
US (1) US12473337B2 (enExample)
JP (2) JP2021521822A (enExample)
KR (1) KR20210024446A (enExample)
CN (2) CN110396133B (enExample)
AU (1) AU2019261411B2 (enExample)
BR (1) BR112020021791A2 (enExample)
CA (1) CA3097995A1 (enExample)
EA (1) EA202092459A1 (enExample)
WO (1) WO2019209965A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200306301A1 (en) 2017-07-03 2020-10-01 Torque Therapeutics, Inc. Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
EP3930687A4 (en) 2019-02-25 2023-06-07 The University of Chicago METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS
CN114341189A (zh) 2019-06-12 2022-04-12 奥美药业有限公司 全新il-15前药及其应用
AU2020316002B2 (en) * 2019-07-25 2026-05-07 The University Of Chicago Compositions and methods comprising protease-activated therapeutic agents
AU2021205981A1 (en) 2020-01-11 2022-07-14 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
BR112022019708A2 (pt) * 2020-04-01 2022-12-20 Xilio Dev Inc Citocina il-12 mascarada, produtos de clivagem, ácidos nucleicos, vetor, célula hospedeira, composições, kit, método de produção de uma citocina il-12 mascarada e métodos de tratamento ou prevenção de câncer
EP4251187A4 (en) * 2020-11-25 2025-09-10 Xilio Dev Inc TUMOR-SPECIFIC CLASSIBLE LINKERS
WO2022129313A1 (en) * 2020-12-18 2022-06-23 F. Hoffmann-La Roche Ag Precursor proteins and kit for targeted therapy
WO2022204267A1 (en) * 2021-03-24 2022-09-29 Alkermes, Inc. Upar antibodies and fusion proteins with the same
WO2022226073A1 (en) * 2021-04-21 2022-10-27 Cue Biopharma, Inc. Mhc class ii t-cell modulatory polypeptides and methods of use thereof
AU2022314734A1 (en) 2021-07-19 2024-02-08 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
IL312221A (en) 2021-10-20 2024-06-01 Synthekine Inc Heterodimeric fc cytokines and uses thereof
AU2024207005A1 (en) * 2023-01-13 2025-08-28 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
EP4695282A1 (en) 2023-04-12 2026-02-18 Shanghai Kangabio Co., Limited Multifunctional molecules comprising masked interleukin 12 and methods of use
CN122349538A (zh) * 2023-12-07 2026-07-07 上海药明生物技术有限公司 针对il-12受体的异二聚体蛋白
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof
WO2025256578A1 (zh) * 2024-06-12 2025-12-18 龙启生物制药(杭州)有限公司 Treg细胞靶向IL12融合蛋白及其制备、治疗方法
WO2026020161A1 (en) * 2024-07-19 2026-01-22 Cytomx Therapeutics, Inc. Activatable il-12 constructs and related compositions and methods

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
ATE311895T1 (de) 1992-05-26 2005-12-15 Immunex Corp Neue zytokine die cd30 binden
AU1407997A (en) * 1995-12-01 1997-06-19 Beth Israel Hospital Il-12 p40 subunit fusion polypeptides and uses thereof
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
EP1835030A1 (en) 1996-12-20 2007-09-19 Amgen, Inc. OB fusion protein compositions and methods
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
ATE407697T1 (de) 1999-07-13 2008-09-15 Bolder Biotechnology Inc Erythropoietin immunglobulin fusionsproteine
EP1418184A1 (en) * 2002-11-08 2004-05-12 Cell Center Cologne GmbH Recombinant fusion protein consisting of the p40 and p35 subunits of IL-12 and a ScFv and use thereof
EP1673395A1 (en) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
JP4718274B2 (ja) 2005-08-25 2011-07-06 東京エレクトロン株式会社 半導体製造装置，半導体製造装置の流量補正方法，プログラム
EP1969000A2 (en) 2005-12-06 2008-09-17 Centre National de la Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2015124297A1 (en) * 2014-02-19 2015-08-27 Merck Patent Gmbh Cancer-targeted il-12 immunotherapy
CN105543279A (zh) * 2014-10-30 2016-05-04 常州卡斯比生物科技有限公司 一种防治辐射线损伤、肿瘤治疗的IL-12/Fc融合蛋白的制备方法及其药剂
CN104628870A (zh) * 2015-02-04 2015-05-20 中国药科大学 一种人IL12Rβ1-CHR蛋白及其Fc融合蛋白
CN105218682B (zh) * 2015-10-26 2019-05-07 杨晶 经il-12/cd62l融合蛋白改造的肿瘤治疗剂及其制法和用途
EP3184548A1 (en) * 2015-12-23 2017-06-28 Miltenyi Biotec GmbH Chimeric antigen receptor with cytokine receptor activating or blocking domain
EP3511340B1 (en) * 2016-08-10 2024-10-02 Ajou University Industry-Academic Cooperation Foundation Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same
WO2018030806A1 (ko) * 2016-08-10 2018-02-15 아주대학교산학협력단 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물

Also Published As

Publication number Publication date
CN110396133B (zh) 2021-07-23
CN110396133A (zh) 2019-11-01
WO2019209965A3 (en) 2019-12-05
JP2021521822A (ja) 2021-08-30
KR20210024446A (ko) 2021-03-05
WO2019209965A2 (en) 2019-10-31
US20220162280A1 (en) 2022-05-26
EA202092459A1 (ru) 2021-06-15
CN112638938A (zh) 2021-04-09
JP2025032113A (ja) 2025-03-11
EP3810639A2 (en) 2021-04-28
AU2019261411B2 (en) 2024-11-14
CA3097995A1 (en) 2019-10-31
AU2019261411A1 (en) 2020-11-26
US12473337B2 (en) 2025-11-18

Similar Documents

Publication Publication Date Title
US12473337B2 (en) Homodimeric or heterodimeric interleukin 12 fusion proteins, and compositions and therapeutic methods thereof
US12441781B2 (en) Interleukin 15 fusion proteins, and compositions and therapeutic methods thereof
JP3652582B2 (ja) タイプｉｉインターロイキン−１受容体
AU2024219567A1 (en) Cytokine-based bioactivatable drugs and methods of uses thereof
US12497439B2 (en) Multi-functional fusion proteins and uses thereof
RU2262510C2 (ru) Слитый белок, обладающий биологической активностью интерферона-альфа, димерный слитый белок, фармацевтическая композиция, их содержащая, молекула днк (варианты) и способ адресования интерферона-альфа в ткани печени
US12522639B2 (en) Heterodimeric FC cytokines and uses thereof
US20220402988A1 (en) Interleukin 15 fusion proteins and prodrugs, and compositions and methods thereof
BR112016002614B1 (pt) Imunocitoquina e composição farmacêutica
AU2023327477A1 (en) IL-15 MUTANT-FC/IL-15Rα SUBUNIT-FC HETERODIMER AND USE THEREOF
US20260070957A1 (en) Interleukin 15 fusion proteins, and compositions and therapeutic methods thereof
JP4579688B2 (ja) Ｉｌ−１８ｂｐのプロモーター、その製造および使用
HK40050873A (en) Interleukin 12 fusion proteins, and compositions and therapeutic methods thereof
HK40050872A (en) Interleukin 15 fusion proteins, and compositions and therapeutic methods thereof
HK1082510B (en) Promoter to il-18bp, its preparation and use

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2877 DE 24-02-2026 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.